
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic Inc's positive outlook is bolstered by encouraging Phase 1b data demonstrating a dose-dependent increase in GLP-1 levels, which may correlate to potential therapeutic benefits in patients and could facilitate future strategic partnerships for IMU-856. Furthermore, preclinical studies indicate promising outcomes for vidofludimus calcium (IMU-838) regarding its neuroprotective properties and efficacy in reducing body weight gain, suggesting a multifaceted approach to treating multiple sclerosis. With the upcoming top-line data from the CALLIPER trial in April 2025 and continued positive results from the Phase 3 ENSURE program, Immunic is well-positioned to advance its pipeline of innovative immunology therapies.
Bears say
Immunic Inc faces significant risks that contribute to a negative outlook on its stock, including the potential failure of its developmental candidates to achieve projected peak commercial revenues due to factors such as market size, penetration rates, and pricing challenges. Additionally, the company's ability to secure necessary capital resources for ongoing operations is uncertain, which may hinder its growth and development efforts. Furthermore, there are ongoing concerns regarding the progress of program development and commercialization, which could further impact financial sustainability.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares